On February 23, 2021, in connection with the IPO, Mr. Troy Cox, Mr. Kevin Conroy, Dr. Jason Kelly and Dr. Stephen Quake (collectively, the “Directors”) were appointed to the board of directors of CM Life Sciences II Inc. The Directors are independent directors. Effective February 23, 2021, Mr. Conroy, Mr. Cox and Dr. Kelly were appointed to the Board’s Audit Committee, with Mr. Cox serving as chair of the Audit Committee; Mr. Conroy, Mr. Cox and Dr. Quake were appointed to the Board’s Compensation Committee, with Mr. Conroy serving as chair of the Compensation Committee; and Mr. Cox, Dr. Kelly and Mr. Meister were appointed to the Nominating and Corporate Governance Committee, with Dr. Kelly serving as chair of the Nominating and Corporate Governance Committee. Following the appointment of the Directors, the Board is comprised of the following three classes: the term of office of the first class of directors, Class I, consists of Drs. Kelly and Quake and will expire at the Company’s first annual meeting of stockholders; the term of office of the second class of directors, Class II, consists of Messrs. Conroy and Cox and will expire at the Company’s second annual meeting of stockholders; and the term of office of the third class of directors, Class III, consists of Messrs. Casdin and Meister and will expire at the Company’s third annual meeting of stockholders.